Shoaib Abdullah B, Machie Michelle, Thomas Jennifer M, Dolce Alison
Division of Neurology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas; Children's Medical Center Dallas, Children's Health, Dallas, Texas.
Division of Neurology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas; Children's Medical Center Dallas, Children's Health, Dallas, Texas.
Pediatr Neurol. 2023 Sep 30;149:176-181. doi: 10.1016/j.pediatrneurol.2023.09.021.
A retrospective study was conducted to assess the safety and efficacy of lacosamide in children aged less than 24 months.
Patients were included if they were ≤24 months when they first received lacosamide; patients were excluded if they were enrolled in research studies investigating lacosamide or if there were insufficient data in the chart. Treatment response was assessed by reviewing charts and electroencephalographic reports to determine reduction in seizure burden.
In this sample, 53 of 86 patients (61.63%) in status epilepticus had good response to lacosamide, defined by ≥50% reduction in seizure burden. In addition, patients' charts were reviewed until age 24 months to assess for any adverse effects attributed to maintenance lacosamide therapy, with adverse effects noted in three patients (abnormal movements in two patients, worsened seizures in one patient).
This study is among the largest retrospective chart reviews investigating the use of lacosamide in children and the first investigating the efficacy of lacosamide in children aged ≤24 months. Lacosamide was efficacious in reducing seizure burden in status epilepticus, and it was very well-tolerated in this age group. This study should prompt further investigation into the use of lacosamide in this age group.
开展一项回顾性研究，以评估拉科酰胺用于24个月以下儿童的安全性和有效性。
首次接受拉科酰胺治疗时年龄≤24个月的患者纳入研究；参加拉科酰胺相关研究或病历资料不足的患者排除。通过查阅病历和脑电图报告评估治疗反应，以确定癫痫发作负荷的降低情况。
在该样本中，86例癫痫持续状态患者中有53例（61.63%）对拉科酰胺反应良好，定义为癫痫发作负荷降低≥50%。此外，对患者病历进行随访至24个月，以评估维持拉科酰胺治疗的任何不良反应，3例患者出现不良反应（2例患者有异常运动，1例患者癫痫发作加重）。
本研究是调查拉科酰胺用于儿童的最大规模回顾性病历审查之一，也是首次调查拉科酰胺用于≤24个月儿童的疗效。拉科酰胺在降低癫痫持续状态的癫痫发作负荷方面有效，且该年龄组对其耐受性良好。本研究应促使对该年龄组使用拉科酰胺进行进一步研究。
